1 citations
,
July 2025 in “Clinical and Experimental Dermatology” Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.
2 citations
,
March 2010 in “Acta Biochimica Polonica” Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.
March 2024 in “EMBO molecular medicine” Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.
January 2023 in “International Journal of Trichology” Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.
9 citations
,
May 2022 in “Drugs in Context” Sonidegib effectively treated advanced basal cell carcinoma with mild side effects.
4 citations
,
January 2016 in “Dermatology Review” Cancer treatments often cause skin, nail, and hair problems.
108 citations
,
December 2003 in “Clinical breast cancer” PLD is an effective and safer alternative for treating breast cancer.
12 citations
,
March 2016 in “Life Sciences” The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.
33 citations
,
January 2018 in “Blood” Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
March 2025 in “Future Oncology” Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.
25 citations
,
May 2018 in “Clinical & Translational Oncology” New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.
15 citations
,
January 2019 in “Journal of the Formosan Medical Association” Adalimumab helped control a child's severe eye disease when other treatments failed.
5 citations
,
June 2001 in “Annals of Internal Medicine” Rituximab effectively treated a woman's bone lymphoma that was resistant to other treatments.
1 citations
,
January 2026 in “International Journal of Dermatology” Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.
1 citations
,
July 2014 in “International Journal of Dermatology” A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.
July 2024 in “Journal of Investigative Dermatology” Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.
12 citations
,
September 2020 in “Nanomaterials” The new drug delivery system improves vitiligo treatment by enhancing melanocyte activity and viability.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Oral minoxidil can help regrow hair lost from antibody-drug conjugate treatment.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
1461 citations
,
March 2004 in “Annals of oncology” Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.
88 citations
,
July 2014 in “Journal of the American Academy of Dermatology” Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
67 citations
,
October 2005 in “Annals of Oncology” Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
17 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
October 2015 in “Elsevier eBooks” Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.
September 2022 in “Journal of Sulaimani Medical College” The combination treatment showed some improvement but wasn't significantly better than using betamethasone valerate alone.
February 2024 in “Frontiers in Cell and Developmental Biology” Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
April 2016 in “Journal of Investigative Dermatology” Microneedle arrays deliver botulinum toxin effectively for sweat suppression, similar to injections.
4 citations
,
September 2024 in “BMC Cancer” 1 citations
,
August 1983 in “PubMed” CVP therapy showed moderate success in treating advanced non-Hodgkin's lymphoma, but more intensive treatment is needed for better outcomes.